Moderna

Five years ago, a novel virus emerged in Wuhan, China, leading to a global pandemic. Its origin remains uncertain, with theories suggesting animal transmission or a lab leak. Over 20 million deaths are estimated worldwide. Vaccines, developed rapidly, have saved millions but require updates for evolving variants like omicron. Long COVID affects millions with persistent symptoms, its cause and treatment still unclear.

CARsgen Therapeutics' CAR-T therapy, satri-cel, shows efficacy in treating advanced gastric cancer, marking a significant advancement for CAR-T in solid tumors. Positive phase 2 trial results may lead to a regulatory filing in China, potentially making it the first CAR-T product for solid tumors. Claudin 18.2, a tumor-specific target, plays a key role in this breakthrough.

Metformin lowers COVID-19 viral loads; long COVID affects brain function for years. HLA gene variant linked to asymptomatic infections. COVID symptoms include diarrhea, nausea. Free at-home tests ended; oral antivirals available until 2024. Vaccination may delay menstrual cycle. Omicron and its subvariants dominate, with KP.2 and JN.1 being notable. Long COVID symptoms include fatigue, brain fog. Vaccines' myocarditis risk is low. Pregnant vaccinated women have higher COVID risk. No elevated stroke/heart attack rates post-vaccination. J&J vaccine limited due to blood clot risk.

DelveInsight partnered with a pharmaceutical company to evaluate CDMO companies for API and FD development, providing a detailed report on R&D, manufacturing, and commercialization capabilities. The CDMO market, valued at USD 100.02 billion in 2021, is projected to grow to USD 143.87 billion by 2030, driven by demand for innovative therapies. Strategic partnerships and acquisitions, especially during the COVID-19 pandemic, have further fueled market growth. DelveInsight's methodology includes comprehensive evaluation of CDMO capabilities, ensuring clients select the most suitable partners for outsourcing projects.

In 2024, gastrointestinal infections posed significant public health risks, with outbreaks of *E coli*, *Salmonella*, and Norovirus. Efforts to enhance food safety and research into vaccines and microbiome therapies progressed. Vulnerable populations faced higher risks, emphasizing the need for vigilance, regulation, and innovation in combating these diseases.

DermTech’s 2-GEP assay aids biopsy decisions for skin lesions. Dermoscopy with RCM boosts diagnostic accuracy. SXRT offers a non-surgical option for BCC and SCC. Traveling screenings enhance skin cancer awareness. New tools predict melanoma metastasis risk. Mohs surgery advocated for prison populations. OCT optimizes BCC mapping. Melanoma diameter correlates with survival. Sonidegib plus calcium aids BCC management. Moderna and Merck advance melanoma treatment. Skin cancer treatment options need expansion. Lifileucel and pembrolizumab evaluated for melanoma. New guidelines for nonmelanoma skin cancer published. Surgery superior for SCC in situ. Melanoma screening adherence moderate. IBI363 fast-tracked for advanced melanoma. Disparities in melanoma care highlighted. DermaSensor aids lesion differentiation. 5-Fluorouracil improves SCC treatment in older patients. Melanoma impacts employment. Motivations key to clinical trial success. Pediatric melanoma considerations provided. Heart transplant recipients more prone to skin cancer. New algorithm for lipase monitoring in melanoma. Coaches crucial in UV education for athletes.

COVID-19 research reveals SARS-CoV-2 variants' impact on vaccine effectiveness, emphasizing the need for updated vaccines and booster shots. Variants like B.1.1.7, B.1.351, and P.1 show increased transmissibility and immune evasion, challenging public health responses. Global surveillance and adaptation of vaccination strategies are crucial for managing the pandemic.

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.